To the Editor In December of 2019,a widespread outbreak of novel coro-navirus pneumonia(NCP)occurred in Wuhan,China.On January 12,2020,the virus causing NCP was named as“2019-nCoV”by the World Health Organization[1,...To the Editor In December of 2019,a widespread outbreak of novel coro-navirus pneumonia(NCP)occurred in Wuhan,China.On January 12,2020,the virus causing NCP was named as“2019-nCoV”by the World Health Organization[1,2].The World Health Organization renamed NCP as“COVID-19”.COVID-19 is a highly contagious respiratory virus that poses a serious threat to human health worldwide.At present,COVID-19 has been classified as a Class B infectious disease in China,and management of Class A infectious diseases has been adopted.As of March 10,2020,80932 cases were diagnosed and confirmed as COVID-19 in China,with 60002 cured cases and 3140 death.Meanwhile,34656 cases were diagnosed and confirmed as COVID-19 abroad.展开更多
The biocompatibility of surface-modified biphasic calcium phosphate （mBCP）/poly-L-Lactide （PLLA） biocomposite was investigated through a series of experiments in vitro and in vivo. Acute toxicity and short term sy...The biocompatibility of surface-modified biphasic calcium phosphate （mBCP）/poly-L-Lactide （PLLA） biocomposite was investigated through a series of experiments in vitro and in vivo. Acute toxicity and short term systemic toxicity experiments revealed no toxicity of the materials. Hemolysis assay indicated the good blood compatibility of the composite. In cytotoxicity assay, L929 mouse fibroblasts could well differentiate and proliferate. Animal experiments in vivo were.performed by implanting the materials into rabbits muscle for 8 weeks. The decreasing of inflammatory cells, the building of fibrous tissue layer as well as the growing of blood cells into materials indicated the nontoxicity of the composite. Based on the experiment results, surfacemodified BCP/PLLA biocomposite is proven to have superior biocompatibility, which would be a promising bone repairing material.展开更多
文摘To the Editor In December of 2019,a widespread outbreak of novel coro-navirus pneumonia(NCP)occurred in Wuhan,China.On January 12,2020,the virus causing NCP was named as“2019-nCoV”by the World Health Organization[1,2].The World Health Organization renamed NCP as“COVID-19”.COVID-19 is a highly contagious respiratory virus that poses a serious threat to human health worldwide.At present,COVID-19 has been classified as a Class B infectious disease in China,and management of Class A infectious diseases has been adopted.As of March 10,2020,80932 cases were diagnosed and confirmed as COVID-19 in China,with 60002 cured cases and 3140 death.Meanwhile,34656 cases were diagnosed and confirmed as COVID-19 abroad.
基金supported by Doctoral Fund of Ministry of Education of China under grant No.20060610024
文摘The biocompatibility of surface-modified biphasic calcium phosphate （mBCP）/poly-L-Lactide （PLLA） biocomposite was investigated through a series of experiments in vitro and in vivo. Acute toxicity and short term systemic toxicity experiments revealed no toxicity of the materials. Hemolysis assay indicated the good blood compatibility of the composite. In cytotoxicity assay, L929 mouse fibroblasts could well differentiate and proliferate. Animal experiments in vivo were.performed by implanting the materials into rabbits muscle for 8 weeks. The decreasing of inflammatory cells, the building of fibrous tissue layer as well as the growing of blood cells into materials indicated the nontoxicity of the composite. Based on the experiment results, surfacemodified BCP/PLLA biocomposite is proven to have superior biocompatibility, which would be a promising bone repairing material.
